SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Silence Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.58+10.90 (+125.58%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$13.08 (+201.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Silence Therapeutics plc saw revenue fall 97.7% to $615.00K over the twelve months to Jun 30, 2026. Free cash flow was -$42.27M.
Revenue
$615.00K
-97.7% vs. a year earlier
Operating income
-$68.31M
TTM Q2 2026
Free cash flow
-$42.27M
TTM Q2 2026
EPS, diluted
-$0.43
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.77B
- P/E ratio
- –
- Price to sales
- 4511.67
- Price to book
- 72.12
- Dividend yield
- –
- Free cash flow yield
- -1.52%
Fundamentals
- Revenue
- $615.00K
- Net income
- -$59.95M
- EPS, diluted
- -$0.43
- Free cash flow
- -$42.27M
- Book value per share
- $0.27
- Diluted shares
- 142M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$615.00K-97.7% YoY
Gross profit
$528.00K-97.5% YoY
Operating income
-$68.31M
Net income
-$59.95M
EPS, diluted
-$0.43
Free cash flow
-$42.27M
Reported periodTrailing twelve months